Ignite Creation Date:
2024-05-06 @ 7:47 AM
Last Modification Date:
2024-10-26 @ 11:52 AM
Study NCT ID:
NCT02600923
Status:
COMPLETED
Last Update Posted:
2022-01-20
First Post:
2015-11-06
Brief Title:
Palbociclib Plus Letrozole For Postmenopausal Women With HR HER2- Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Sponsor:
Pfizer
Organization:
Pfizer
Organization Data
Organization:
Pfizer
Class:
INDUSTRY
Study ID:
A5481053
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Pfizer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None